Tech Company Financing Transactions
Cara Therapeutics Funding Round
Cara Therapeutics, based in Stamford, secured $12.3 million from Devon Park Bioventures, Alta Partners and Ascent Venture Partners.
Transaction Overview
Company Name
Announced On
7/25/2008
Transaction Type
Venture Equity
Amount
$12,300,000
Round
Series C
Investors
Devon Park Bioventures (Lead Investor) (Christopher Moller)
Alta Partners (Ed Hurwitz)
Proceeds Purpose
The additional funds will be used primarily for further clinical development of both intravenous and oral formulations of Cara's second generation peripherally-selective kappa opioid agonist, CR845.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
4 Stamford Plz. 107 Elm St. 9th Floor
Stamford, CT 06902
USA
Stamford, CT 06902
USA
Phone
Website
Email Address
Overview
Cara Therapeutics is a biotechnology company focused on developing therapeutics to treat diseases associated with pain and inflammation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Derek Chalmers
Chief Financial Officer
Mani Mohindru
Chief Scientific Officer
Michael Lewis
VP - General Counsel
Scott Terrillion
VP - Operations
Eric Vandal
VP - R & D
Frédérique Menzaghi
Browse more venture capital transactions:
Prev: 7/24/2008: NuPathe venture capital transaction
Next: 7/25/2008: Slate Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs